Skip to content
drillr.ai

IPSC

Century Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$2.19-2.67%

Price as of Jul 20, 2026

IPSC news

Century Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

    PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses: * 62(nd) Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–Octob

    Globe Newswire ·

  2. New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

    * Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes * CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical models * Allo-Evasion™ 5.0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse model without immunosuppression * Phase 1 clinical manufacturing process has been established demonstrating consistent endocrine purity and optim

    Globe Newswire ·

  3. Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

    * CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H 2027 * CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, on track to enter the clinic in 2026 * Strengthened balance sheet and cash runway extended into 1Q 2029 from oversubscribed $135 million private placement in January 2026 PH

    Globe Newswire ·

  4. Century Therapeutics to Participate in Upcoming Investor Conferences in March

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNXbYGShZ&default-theme=true PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will part

    Globe Newswire ·